{
  "id": "adv_mhgap#risk_safety_5b45b8c4",
  "content": "25\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nrisks when driving, operating machinery, etc.; the for benzodiazepine withdrawal and dependance;\nlikely time to improvement in symptoms; and the for further information, see the 2015 Update of the\npotential for addiction. Mental Health Gap Action Programme (mhGAP)\ny Discontinue benzodiazepines gradually as soon as guidelines for mental, neurological and substance\nsymptoms improve to avoid tolerance. use disorders (7) and the 2016 mhGAP intervention\ny For adults who demonstrate potential signs of guide module on “Disorders due to substance\ndependance, consider management approaches use” (9).\nANX7. Is collaborative care better than (more effective than/as safe as)\ntreatment as usual, waitlist, no treatment for adults with\ndepression or anxiety (living with chronic health conditions)?\nRecommendation (new): Collaborative care should be considered for adults with depression and/or\nanxiety and physical health conditions.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification – approaches to identifying people in need of\ny Evidence was extracted from three systematic support (through use of systematic screening or\nreviews: Xiao et al., 2021 (89 RCTs on case identification);\npharmacological interventions for adults with GAD) – implementation of evidence-based interventions",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Risk Safety 25\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nrisks when driving, operating machinery, etc.; the for benzodiazepine withdrawal and dependance;\nlikely time to improvement in symptoms; and the for further information, see the 2015 Update of the\npotential for addiction. Mental Health Gap Action Programme (mhGAP)\ny Discontinue benzodiazepines gradually as soon as guidelines for mental, neurological and substance\nsymptoms improve to avoid tolerance. use disorders (7) and the 2016 mhGAP intervention\ny For adults who demonstrate potential signs of guide module on “Disorders due to substance\ndependance, consider management approaches use” (9).\nANX7. Is collaborative care better than (more effective than/as safe as)\ntreatment as usual, waitlist, no treatment for adults with\ndepression or anxiety (living with chronic health conditions)?\nRecommendation (new): Collaborative care should be considered for adults with depression and/or\nanxiety and physical health conditions.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification – approaches to identifying people in need of\ny Evidence was extracted from three systematic support (through use of systematic screening or\nreviews: Xiao et al., 2021 (89 RCTs on case identification);\npharmacological interventions for adults with GAD) – implementation of evidence-based interventions 25\nmental health gap action programme (mhgap) guideline for mental, neurological and substance use disorders\nrisks when driving, operating machinery, etc.; the for benzodiazepine withdrawal and dependance;\nlikely time to..."
}